bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)

Industrial manufacturing of recombinant semaglutide GLP-1 receptor agonists combining high-density fed-batch fermentation of Pichia pastoris or E. coli with enzymatic leader cleavage and selective Lys26 acylation with a mono-fatty diacid hydrophilic spacer.

1 · What it gives

Recombinant semaglutide production represents a multi-billion-dollar frontier in peptide therapeutics, shifting metabolic disorder and obesity management from chemical solid-phase synthesis to precision microbial fermentation. Semaglutide is a 31-amino-acid GLP-1 receptor agonist featuring a synthetic C18 diacid-fatty acid chain attached via an AEEA-AEEA-gamma-Glu hydrophilic spacer to Lys26, imparting a 165-hour half-life. Recombinant biosimilar production relies on high-density fed-batch fermentation of genetically engineered Escherichia coli or Pichia pastoris producing a soluble or inclusion-body fusion protein precursor (such as SNAC-tagged or leader-sequence protected P29 intermediate).

Following harvest, site-specific enzymatic cleavage by engineered enterokinase, trypsin, or carboxypeptidase B yields the pristine peptide core at titers surpassing 4.5 g/L with >95% cleavage specificity. Subsequent chemoselective fatty-acid side-chain acylation using activated N-hydroxysuccinimide esters, followed by multi-step orthogonal preparative reverse-phase and ion-exchange HPLC, achieves >99.5% chromatographic purity with host cell protein (HCP) levels under 5 ppm and single-isomer chiral integrity compliant with USP and Ph. Eur. monographs.

The key directions of this technology are:

  1. High-Density Recombinant Precursor Fermentation: Optimizing fed-batch expression in Pichia pastoris or E. coli with codon-optimized fusion cassettes to express soluble or inclusion-body GLP-1 backbone intermediates at >5 g/L.
  2. Site-Specific Proteolytic Enzyme Cleavage: Engineering immobilized, recombinant enterokinase or specialized endopeptidases for quantitative, non-degrading cleavage of fusion tags without C-terminal ragged ends.
  3. Regioselective Hydrophilic Spacer & Fatty-Acid Acylation: Executing chemoselective coupling of alpha,omega-dicarboxylic octadecanedioic acid mono-tert-butyl ester through AEEA-AEEA-gamma-Glu linkers specifically to the Lys26 epsilon-amino group.
  4. Multi-Column Orthogonal Preparative RP-HPLC: Deploying high-pressure preparative chromatography on polymeric and C18 silica stationary phases using gradient ethanol/acetonitrile buffers to eliminate Des-Gly or D-amino acid impurities.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Engineered Microbial Chassis & Fermentation   │
│  (Pichia pastoris / E. coli fed-batch expression)      │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Fusion Precursor Harvest & Enzymatic Cleavage │
│  (Cell lysis, inclusion body refolding, enterokinase)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Chemoselective Fatty Acid Acylation           │
│  (Lys26 targeting with AEEA-gamma-Glu-C18 diacid tag)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Preparative Chromatography & Polishing        │
│  (Orthogonal RP-HPLC & IEX, solvent recovery >90%)     │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Lyophilization & Final Aseptic Formulation    │
│  (Injectable solutions, pen-injectors, oral co-crystal)│
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Upstream Microbial Host FermentationHigh-cell-density aerobic fermentation in 10,000 L stainless steel bioreactors with dissolved oxygen cascade control and methanol/glycerol feeding strategies.In: Engineered Pichia pastoris clones, defined mineral salts, methanol/glycerol feed.
Out: Clarified fermentation broth or harvested inclusion bodies containing fusion peptide at >4.5 g/L.
Enzymatic Digestion & Primary Peptide PurificationLysis, tangential flow ultrafiltration (10 kDa MWCO), and enzymatic cleavage with recombinant immobilized enterokinase in packed-bed reactors.In: Crude fusion protein, immobilized enterokinase, pH 7.8 tris buffer.
Out: Des-fatty acid GLP-1 precursor core peptide at >92% molar recovery.
Stereospecific Side-Chain Chemical ConjugationRegioselective acylation of the un-cleaved epsilon-amino moiety of Lys26 in binary aqueous-organic solvent systems under strictly controlled pH 9.5–10.2.In: Core peptide, activated C18-diacid-AEEA-gamma-Glu-OSu ester.
Out: Crude mono-acylated semaglutide solution with <3% bis-acylated side products.
Orthogonal Preparative Chromatographic PurificationIndustrial preparative high-performance liquid chromatography using 10 µm C18 bonded spherical silica columns and ammonium acetate/acetonitrile gradient mobile phases.In: Crude acylated semaglutide, food-grade ethanol/acetonitrile, deionized water.
Out: High-purity fraction pools exceeding 99.5% purity with <0.1% individual diastereomers.
Lyophilization, Formulation & Aseptic Fill-FinishDrying bulk purified solution in pharmaceutical-grade lyophilizers, followed by sterile reconstitution with phenol, propylene glycol, disodium phosphate, and water for injection.In: Purified semaglutide API, compendial excipients, sterile glass cartridges.
Out: Finished pharmaceutical pre-filled pens and sterile vials complying with cGMP standards.

Cross-cutting technologies of the sector:

  • Preparative Reverse-Phase HPLC: Provides high-resolution single-amino-acid impurity separation essential for complex biosimilar peptide release.
  • Process Analytical Technology (PAT): Integrates in-line UHPLC and mass spectrometry to track enzymatic cleavage kinetics and acylation completeness in real time.
  • Continuous Lyophilization & Spray-Drying: Stabilizes hydrophobic, aggregation-prone glucagon-like peptide analogs into amorphous or microcrystalline bulk API.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 5 steps

  1. 1
    processing
    Who can do this step matched automatically
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
    Pfizer Global
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
  2. 2
    processing
    Who can do this step matched automatically
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
    Pfizer Global
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
  3. 3
    processing
    Who can do this step matched automatically
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
    Pfizer Global
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
  4. 4
    processing
    Who can do this step matched automatically
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
    Pfizer Global
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
  5. 5
    processing
    Who can do this step matched automatically
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”
    Pfizer Global
    ✓ ISO 9001 industrial scale
    “Industrial supplier for Recombinant Semaglutide Production (Recombinant Yeast/E. coli Expression, Cleavage and Fatty Acid Acylation)”

4 · Who delivers

Matched suppliers (matched automatically)

ORF GeneticsIcelandProduceractive
Zero Cow FactoryIndiaProduceractive
LoopwormIndiaProduceractive
Jiangsu Jland BiotechChinaProduceractive
Dyadic InternationalUnited StatesProduceractive
Jiangsu TrautecChinaProduceractive
Spiber Technologies ABSwedenResearch / RTOactive
Giant Biogene HoldingChinaDistributoractive
IsomeraseUnited KingdomProduceractive
Ecogreen OleochemicalsIndonesiaProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Novo Nordisk🇩🇰 DenmarkOzempic / Wegovy / RybelsusInnovator and patent holder; engineered recombinant yeast expression and proprietary oral SNAC co-formulationcommercial
Phenotypeca🇬🇧 United KingdomS. cerevisiae Recombinant Semaglutide PlatformPioneered high-yield Saccharomyces cerevisiae breeding platforms for low-cost biosimilar semaglutide expressioncommercial
Geropharm🇷🇺 RussiaSemavik (Recombinant Semaglutide)First authorized Russian biosimilar manufacturer producing recombinant active substance and pre-filled pens domesticallycommercial
Huadong Medicine🇨🇳 ChinaRecombinant GLP-1 Biosimilar PipelineLeading Chinese pharmaceutical developer operating commercial 20,000 L microbial fermentation capacity for semaglutidecommercial
Biocon🇮🇳 IndiaGlobal Recombinant Peptide CDMOMajor international generic and biosimilar producer with large-scale Pichia pastoris fermentation and RP-HPLC polishingcommercial
Bachem🇨🇭 SwitzerlandSynthetic and Hybrid Peptide APIWorld-leading peptide contract development and manufacturing organization (CDMO) supplying high-purity peptide intermediatescommercial

5 · Rules & route to market

United States

FDA 505(b)(2) Abbreviated Regulatory Pathways & Biosimilar Competition#

  • The US market is the world’s largest commercial territory for GLP-1 agonists, driven by Medicare expansion, commercial obesity reimbursement, and FDA draft guidances on synthetic and recombinant peptide biosimilar sameness.
  • FDA guidelines (21 CFR 314.94) require peptide biosimilar applicants to demonstrate identical primary sequence, secondary folding via 2D NMR, and absence of immunogenic novel peptide-related impurities above 0.10%.
  • Major US contract manufacturers and domestic biotechs are aggressively securing patent carve-outs and developing off-patent recombinant production infrastructure ahead of key patent expiries.

European Union

Stringent EMA CHMP Monograph Compliance & Green Chemical Synthesis#

  • The European Medicines Agency (EMA) enforces strict quality guidelines for synthetic and recombinant peptides (EMA/CHMP/CVMP/QWP/367182/2025), requiring complete tracking of sequence deletion variants.
  • European manufacturing hubs in Switzerland, Denmark, and Germany emphasize green peptide manufacturing, recovering >92% of chromatographic solvents and eliminating hazardous coupling solvents.
  • Academic and industrial consortia collaborate on continuous enzymatic acylation to replace classical stoichiometric carbodiimide coupling chemistry.

China

High-Volume Fermentation Scale & NMPA Biosimilar Fast-Tracking#

  • China has the world’s largest population of diabetic patients, creating intense demand for domestic semaglutide biosimilars to lower national healthcare insurance expenditure.
  • Domestic pharmaceutical champions in Zhejiang, Jiangsu, and Guangdong (such as Gan & Lee, Huadong Medicine, and Livzon) have deployed 20,000-liter microbial fermentation suites to drive unit API costs below $80/gram.
  • The NMPA Center for Drug Evaluation (CDE) has established fast-track clinical trial pathways for recombinant GLP-1 biosimilars, emphasizing immunogenicity equivalence and steady-state pharmacokinetic matching.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Fermentation Host & Expression Optimization:
    • Codon-optimized multi-copy gene cassette integrated into Pichia pastoris genome under the control of the alcohol oxidase 1 (AOX1) promoter.
    • Dissolved oxygen maintained at >30% air saturation during high-density fed-batch fermentation, achieving wet cell weights exceeding 450 g/L.
    • Co-expression of molecular chaperones (PDI and BiP) to minimize intracellular aggregation and enhance soluble fusion peptide secretion.
  2. Enzymatic Digestion & Site-Specific Cleavage:
    • Recombinant bovine enterokinase immobilized on glutaraldehyde-activated porous agarose beads with enzymatic activity >5,000 U/mL.
    • Enzymatic cleavage executed at 25°C, pH 7.8 with residence time <90 minutes, achieving >96% conversion of precursor to native GLP-1 core.
    • Tangential flow filtration with 5 kDa polyethersulfone ultrafiltration membranes recovering >95% of cleaved core peptide while excluding high-molecular-weight proteases.
  3. Acylation Chemistry & Preparative Polishing:
    • Chemo-selective mono-acylation utilizing N-hydroxysuccinimide-activated octadecanedioic acid-gamma-Glu-AEEA-AEEA in 1:1 water:acetonitrile at pH 9.8.
    • Industrial preparative HPLC using 100 mm ID dynamic axial compression columns packed with 10 µm 100 Å spherical C18 silica.
    • Binary gradient elution with 0.1% trifluoroacetic acid in water and acetonitrile, yielding purified semaglutide API with purity >99.5% and single impurity <0.1%.

Sources 2 · 2 independent · 0 producer sites

Independent sources 2

  1. doi.org research checked 2026-11-15
  2. www.ema.europa.eu official checked 2026-11-15